Sudeep Pharma hosts Q1FY27 earnings call on Aug 5 to discuss results
Sudeep Pharma Limited announced an earnings call for August 5, 2026, to discuss its Q1FY27 financial and operational performance. The event, hosted by Nuvama Wealth Management, will include key management personnel such as Managing Director Sujit Bhayani and CFO Ketan Vyas, providing investors with insights into the company's recent quarterly results.
*this image is generated using AI for illustrative purposes only.
Sudeep Pharma Limited will host an earnings call with analysts and investors on Wednesday, August 5, 2026, at 11:00 AM IST. The conference is convened to discuss the company’s operational and financial performance for the quarter ended June 30, 2026 (Q1FY27). This event provides stakeholders with a direct channel to review the latest quarterly results and address queries regarding the company’s strategic direction in the pharmaceutical sector.
The announcement was made in compliance with Regulation 30 of the SEBI Listing Regulations, 2015. The notice was issued on July 27, 2026, by Dimple Mehta, Company Secretary & Compliance Officer of Sudeep Pharma Limited. The invitation includes access details for participants across India, the USA, the UK, Singapore, and Hong Kong, ensuring global investor accessibility.
Conference Call Details
Nuvama Wealth Management is hosting the conference call. Mr. Archit Joshi from Nuvama Wealth Management Ltd. will serve as the call leader. Participants can join via the following dial-in numbers:
| Region | Access Number |
|---|---|
| India (Mumbai) | +91 22 6280 1123 / +91 22 7115 8024 |
| USA | 1 866 746 2133 |
| UK | 0 808 101 1573 |
| Singapore (Toll Free) | 800 101 2045 |
| Hong Kong (Toll Free) | 800 964 448 |
Alternatively, investors may register and access the call via the link provided in the annexure of the original filing, which is also available on the company’s investor relations website.
Management Representation
The following senior executives from Sudeep Pharma Limited will represent the company during the call:
- Sujit Bhayani, Managing Director
- Shanil Bhayani, Director
- Ketan Vyas, Chief Financial Officer
What This Means for Investors
While the filing does not disclose specific financial figures such as net profit or revenue, the scheduling of this call confirms that Q1FY27 results have been finalized and are ready for dissemination. Investors should prepare questions regarding margin trends, order book status, and any operational updates relevant to the pharma sector. The absence of pre-disclosed metrics suggests that the primary source of data will be the live management commentary and any accompanying presentation materials shared during the event.
Historical Stock Returns for Sudeep Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.74% | +2.32% | +30.02% | +79.09% | +46.12% | +46.12% |
How will Sudeep Pharma's Q1FY27 margin trends reflect the ongoing impact of raw material cost fluctuations in the global pharmaceutical supply chain?
What strategic initiatives is management prioritizing to offset potential headwinds from regulatory changes or pricing pressures in key export markets like the USA and UK?
Can management provide visibility into the order book pipeline for Q2FY27, particularly regarding new product launches or contract manufacturing agreements?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
